Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05180721 · ClinicalTrials.gov registry record · NA

A Multi-level Intervention to Increase Access and Use of the Patient Portal

A NA study of Diabetes Mellitus, Type 2 and Patient Education, sponsored by Yale University.

Completed
Registry status
NA
Development phase
26
Enrollment target
2
Study locations

NCT05180721 is a NA study of Diabetes Mellitus, Type 2 and Patient Education that has completed, run by Yale University. The registered enrollment target is 26 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05180721, a NA study of Diabetes Mellitus, Type 2 and Patient Education, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to develop and evaluate a multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).

Interventions

  • BEHAVIORAL Use of patient portal for diabetes management

Study Locations (2)

Connecticut

  • Fair Haven Community Health Center - New Haven
  • Norwalk Community Health Center - Norwalk

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2022-10-03
Est. Completion 2024-07-02
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT05180721

The ClinicalTrials.gov registry entry for NCT05180721 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Use of patient portal for diabetes management is the first listed.

NCT05180721 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05180721 about?

NCT05180721 is a clinical study titled "A Multi-level Intervention to Increase Access and Use of the Patient Portal". The purpose of the study is to develop and evaluate a multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).

What is the current status of trial NCT05180721?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2022-10-03. Estimated completion is 2024-07-02.

What conditions does trial NCT05180721 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Patient Education.

What interventions are being tested in trial NCT05180721?

The interventions under investigation include: Use of patient portal for diabetes management (BEHAVIORAL).

Who is sponsoring clinical trial NCT05180721?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05180721 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.